CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A lower percentage of HIV patients taking Reyataz experienced a rebound in viral levels compared with patients on other protease inhibitors, according to an announcement from Bristol-Myers Squibb, the manufacturer of Reyataz. The study of 419 patients found that 7% of those who switched to Reyataz experienced increasing viral levels, compared with 16% of patients who continued on other protease inhibitors. The company did not identify the other protease inhibitors. (AP)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.